Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients.

Autor: Ghaznavi H; Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Mohammadghasemipour Z; Department of Infectious Disease, School of Medicine, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Shirvaliloo M; Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, 5166614766, Iran., Momeni MK; Department of Internal Medicine, School of Medicine, Clinical Immunology Research Center, Ali IbneAbitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Metanat M; Department of Infectious Disease, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Bu Ali Hospital, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Gorgani F; Department of Infectious Disease, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Bu Ali Hospital, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Abedipour F; Department of Infectious Disease, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Bu Ali Hospital, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Mohammadi M; Department of Biostatistics and Epidemiology, School of Health, Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Sartipi M; Department of Biostatistics and Epidemiology, School of Health, Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Khorashad ARS; Department of Parasitology and Mycology, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Shahraki O; Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Ataee M; Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran., Sheervalilou R; Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran. sheervalilour@tbzmed.ac.ir.; Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran. sheervalilour@tbzmed.ac.ir., Sargazi S; Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, 9816743463, Iran. sgz.biomed@zaums.ac.ir.
Jazyk: angličtina
Zdroj: Inflammopharmacology [Inflammopharmacology] 2022 Oct; Vol. 30 (5), pp. 1645-1657. Date of Electronic Publication: 2022 Jul 14.
DOI: 10.1007/s10787-022-01029-4
Abstrakt: Background: It is known that severe acute respiratory coronavirus 2 (SARS-CoV-2) is the viral strain responsible for the recent coronavirus disease 2019 (COVID-19) pandemic. Current documents have demonstrated that the virus causes a PGE2 storm in a substantial proportion of patients via upregulating cyclooxygenase-2 (COX-2) and downregulating prostaglandin E2 (PGE2)-degrading enzymes within the host cell.
Aim: Herein, we aimed to study how short-term treatment with celecoxib (Celebrex), a selective COX-2 inhibitor, affects demographic features, early symptoms, O 2 saturation, and hematological indices of cases with COVID-19.
Methods: A total of 67 confirmed COVID-19 cases with a mild or moderate disease, who had been referred to an institutional hospital in south-eastern Iran from October 2020 to September 2021, were enrolled. Demographic characteristics, symptoms, and hematological indices of the patients were recorded within different time periods. One-way ANOVA or Kruskal-Wallis tests were used to determine differences between data sets based on normal data distribution.
Results: O 2 saturation was statistically different between the control group and patients receiving celecoxib (p = 0.039). There was no marked difference between the groups in terms of the symptoms they experienced (p > 0.05). On the first days following Celebrex therapy, analysis of complete blood counts showed that white blood cell (WBC) counts were markedly lower in patients treated with a high dose of celecoxib (0.4 g/day) than in controls (p = 0.026). However, mean lymphocyte levels in patients receiving a high dose of celecoxib (0.4 g/day) were markedly higher than in patients receiving celecoxib with half of the dose (0.2 g/day) for one week or the untreated subjects (p = 0.004). Changes in platelet count also followed the WBC alteration pattern.
Conclusion: Celecoxib is a relatively safe, inexpensive, and widely available drug with non-steroidal anti-inflammatory properties. The therapeutic efficacy of celecoxib depends on the administrated dose. Celecoxib might improve disease-free survival in patients with COVID-19.
(© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Databáze: MEDLINE
Externí odkaz: